Background: The hypothalamus regulates basic homeostasis such as appetite, circadian rhythm, autonomic and pituitary functions. Dysregulation in these functions results in the hypothalamic syndrome, a rare disorder of various origins. Since serotonin (5-HT) modulates most of the above-mentioned homeostasis, a defect in the serotonergic system can possibly participate in this syndrome. Methods: We describe a girl suffering from hypothalamic syndrome with a decreased concentration of 5-hydroxytryptophan (5-HTP) and a normal level of tryptophan in the cerebrospinal fluid (CSF) suggesting a functional defect in tryptophan hydroxylase (TPH). TPH is a rate-limiting enzyme in the synthesis of the neurotransmitter 5-HT. Results: Therapeutic intervention with 5-HTP, carbidopa and a specific serotonin reuptake inhibitor significantly improved her clinical symptoms and caused biochemical normalisation of neurotransmitters. Conclusion: The girl described had the typical symptoms of a hypothalamic disorder and a defective serotonergic metabolism, a relationship which has not been reported before. Therapeutic interventions to restore 5-HT metabolism resulted in clinical improvement. We suggest that investigation of 5-HT metabolism in CSF of patients with this rare disorder is included in the aetiological work-up.

Keywords:
Serotonin, Tryptophan hydroxylase, Hypothalamus, TPH2 protein, Obesity
1.
Schaad U, Vassella F, Zuppinger K, Oetliker O: Hypodipsia-hypernatremia syndrome. Helvetica Paediatr Acta 1979;34:63–76.
2.
Plazzi G, Parmeggiani A, Mignot E, Lin L, Scano MC, Posar A, Bernardi F, Lodi R, Tonon C, Barbiroli B, Montagna P, Cico-gnani A: Narcolepsy-cataplexy associated with precocious puberty. Neurology 2006;66:1577–1579.
3.
Veenstra-VanderWeele J, Anderson GM, Cook EH Jr: Pharmacogenetics and the serotonin system: Initial studies and future directions. Eur J Pharmacol 2000;410:165–181.
4.
Patel PD, Pontrello C, Burke S: Robust and tissue-specific expression of TPH2 versus TPH1 in rat raphe and pineal gland. Biol Psychiatry 2004;55:428–433.
5.
Zill P, Buttner A, Eisenmenger W, Moller HJ, Ackenheil M, Bondy B: Analysis of tryptophan hydroxylase I and II MRNA expression in the human brain: a post-mortem study. J Psychiatr Res 2007;41:168–173.
6.
Walther DJ, Bader M: A unique central tryptophan hydroxylase isoform. Biochem Pharmacol 2003;66:1673–1680.
7.
Hong CJ, Tsai SJ, Wang YC: Association between tryptophan hydroxylase gene polymorphism (A218C) and schizophrenic disorders. Schizophr Res 2001;49:59–63.
8.
Lin YM, Chao SC, Chen TM, Lai TJ, Chen JS, Sun HS: Association of functional polymorphisms of the human tryptophan hydroxylase 2 gene with risk for bipolar disorder in Han Chinese. Arch Gen Psychiatry 2007;64:1015–1024.
9.
Reader TA, Ase AR, Le Marec N, Lalonde R: Differential effects of L-tryptophan and buspirone on biogenic amine contents and metabolism in Lurcher mice cerebellum. Neurosci Lett 2000;280:171–174.
10.
Trouillas P: The cerebellar serotoninergic system and its possible involvement in cerebellar ataxia. Can J Neurol Sci 1993;20(suppl 3):S78–S82.
11.
Gazulla J: An update on neurochemistry and pharmacological therapy of the cerebellar ataxias (in Spanish). Rev Neurol 2007;45:31–41.
12.
Katz ES, McGrath S, Marcus CL: Late-onset central hypoventilation with hypothalamic dysfunction: a distinct clinical syndrome. Pediatr Pulmonol 2000;29:62–68.
13.
Di Pasquale E, Morin D, Monteau R, Hilaire G: Serotonergic modulation of the respiratory rhythm generator at birth: an in vitro study in the rat. Neurosci Lett 1992;143:91–95.
14.
DuRivage SK, Winter RJ, Brouillette RT, Hunt CE, Noah Z: Idiopathic hypothalamic dysfunction and impaired control of breathing. Pediatrics 1985;75:896–898.
15.
Boulant JA, Dean JB: Temperature receptors in the central nervous system. Annu Rev Physiol 1986;48:639–654.
16.
Jacobs BL, Azmitia EC: Structure and function of the brain serotonin system. Physiol Rev 1992;72:165–229.
17.
Lin MT, Tsay HJ, Su WH, Chueh FY: Changes in extracellular serotonin in rat hypothalamus affect thermoregulatory function. Am J Physiol 1998;274:R1260–R1267.
18.
Miguez JM, Martin FJ, Aldegunde M: Melatonin effects on serotonin synthesis and metabolism in the striatum, nucleus accumbens, and dorsal and median raphe nuclei of rats. Neurochem Res 1997;22:87–92.
19.
King TS, Steinlechner S, Reiter RJ: Does maximal serotonin N-acetyltransferase activity necessarily reflect maximal melatonin production in the rat pineal gland? Neurosci Lett 1984;48:343–347.
20.
Waldhauser F, Boepple PA, Schemper M, Mansfield MJ, Crowley WF Jr: Serum melatonin in central precocious puberty is lower than in age-matched prepubertal children. J Clin Endocrinol Metab 1991;73:793–796.
21.
Martin JE, Klein DC: Melatonin inhibition of the neonatal pituitary response to luteinizing hormone-releasing factor. Science 1976;191:301–302.
22.
Henderson HL, Hodson DJ, Gregory SJ, Townsend J, Tortonese DJ: Gonadotropin-releasing hormone stimulates prolactin release from lactotrophs in photoperiodic species through a gonadotropin-independent mechanism. Biol Reprod 2008;78:370–377.
23.
Mais V, Yen SS: Prolactin-releasing action of gonadotropin-releasing hormone in hypogonadal women. J Clin Endocrinol Metab 1986;62:1089–1092.
24.
Garas A, Trypsianis G, Kallitsaris A, Milingos S, Messinis IE: Oestradiol stimulates prolactin secretion in women through oestrogen receptors. Clin Endocrinol 2006;65:638–642.
25.
Leibowitz SF, Weiss GF, Shor-Posner G: Hypothalamic serotonin: pharmacological, biochemical, and behavioral analyses of its feeding-suppressive action. Clin Neuropharmacol 1988;11(suppl 1):S51–S71.
26.
Ramaekers VT, Senderek J, Hausler M, Ha-ring M, Abeling N, Zerres K, Bergmann C, Heimann G, Blau N: A novel neurodevelopmental syndrome responsive to 5-hydroxytryptophan and carbidopa. Mol Genet Metab 2001;73:179–187.
27.
Maswood N, Cosmi S, Alfinito PD, Leventhal L, Deecher DC: The role of the selective serotonin reuptake inhibitor fluoxetine in temperature regulation in ovariectomized rat models. Neuroendocrinology 2006;84:330–338.
28.
Dunger DB, Leonard JV, Wolff OH, Preece MA: Effect of naloxone in a previously undescribed hypothalamic syndrome. A disorder of the endogenous opioid peptide system? Lancet 1980;1:1277–1281.
29.
Hayek A, Peake GT: Hypothalamic adipsia without demonstrable structural lesion. Pediatrics 1982;70:275–278.
30.
Gurewitz R, Blum I, Lavie P, Pertzelan A, Stivel M, Weinstein R, Galatzer A, Laron Z: Recurrent hypothermia, hypersomnolence, central sleep apnea, hypodipsia, hypernatremia, hypothyroidism, hyperprolactinemia and growth hormone deficiency in a boy – treatment with clomipramine. Acta Endocrinol 1986;279:468–472.
31.
Proulx F, Weber ML, Collu R, Lelievre M, Larbrisseau A, Delisle M: Hypothalamic dysfunction in a child: A distinct syndrome? Report of a case and review of the literature. Eur J Pediatr 1993;152:526–529.
32.
Fishman LS, Samson JH, Sperling DR: Primary alveolar hypoventilation syndrome (Ondine’s curse). Am J Dis Child 1965;110:155–161.
33.
Nattie EE, Bartlett D, Rozycki AA: Central alveolar hypoventilation in a child: an evaluation using a whole-body plethysmograph. Am Rev Respir Dis 1975;112:259–266.
34.
Frank Y, Kravath RE, Inoue K, Hirano A, Pollak CP, Rosenberg RN, Weitzman ED: Sleep apnea and hypoventilation syndrome associated with acquired nonprogressive dysautonomia: clinical and pathological studies in a child. Ann Neurol 1981;10:18–27.
35.
North KN, Ouvrier RA, McLean CA, Hopkins IJ: Idiopathic hypothalamic dysfunction with dilated unresponsive pupils: report of two cases. J Child Neurol 1994;9:320–325.
36.
Ouvrier R, Nunn K, Sprague T, McLean C, Arbuckle S, Hopkins I, North K: Idiopathic hypothalamic dysfunction: a paraneoplastic syndrome? Lancet 1995;346:1298.
37.
Del Carmen Sanchez M, Lopez-Herce J, Carrillo A, Moral R, Arias B, Rodriguez A, Sancho L: Late-onset central hypoventilation syndrome. Pediatr Pulmonol 1996;21:189–191.
38.
Kobayashi H, Miyamoto J, Hasegawa Y: A sudden death due to central hypoventilation in a 3-year-old boy with idiopathic hypothalamic dysfunction. Clin Pediatr Endocrinol 2003;12:7–11.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.